Table 1.

Recent and Ongoing Trials of Tyrosine Kinase Inhibitors in Lung Disease

Drug	Disease	Trials*	Primary Pathway(s) Targeted
Nintedanib	IPF	Tomorrow INPULSIS 1, 2	VEGF, FGF, PDGF
Nintedanib	LAM	Nintedanib for LAM (phase II)	PDGF, FGF, VEGF
Imatinib	PAH	IMPRES	PDGF, c-KIT
Imatinib	LAM	LAMP-1	VEGF
Imatinib	IPF	Gleevec IPF Study	PDGF
Imatinib	Asthma	KIA	c-KIT
Dasatinib	IPF	Targeting proinflammatory cells in IPF	Src
Sorafenib	PAH	Dosing in patients with PAH (phase I)	VEGF, Raf-1 kinase
Sorafenib	Hepatopulmonary syndrome	SHPS (phase II)	VEGF
Saracatinib	LAM	SLAM-1	Src

Definition of abbreviations: FGF = fibroblast growth factor; IMPRES = Imatinib (QTI571) in Pulmonary Arterial Hypertension study; IPF = idiopathic pulmonary fibrosis; KIA = Effects of c-Kit Inhibition by Imatinib in Patients with Severe Refractory Asthma study; LAM = lymphangioleiomyomatosis; LAMP-1 = LAM Pilot Study with Imatinib Mesylate 1; PAH = pulmonary arterial hypertension; PDGF = platelet-derived growth factor; SHPS = Sorafenib for Hepatopulmonary Syndrome; SLAM-1 = Tolerability of Saracatinib in Subjects with Lymphangioleiomyomatosis; VEGF = vascular endothelial growth factor.

^*Cancer trials excluded (see www.clinicaltrials.gov).